Accounting for indirect protection in the benefit-risk ratio estimation of rotavirus vaccination in children under the age of 5 years, France, 2018
- PMID: 32820718
- PMCID: PMC7441603
- DOI: 10.2807/1560-7917.ES.2020.25.33.1900538
Accounting for indirect protection in the benefit-risk ratio estimation of rotavirus vaccination in children under the age of 5 years, France, 2018
Erratum in
-
Authors' correction for Euro Surveill. 2020;25(32).Euro Surveill. 2020 Oct;25(39):201001c. doi: 10.2807/1560-7917.ES.2020.25.39.201001c. Euro Surveill. 2020. PMID: 33006302 Free PMC article. No abstract available.
-
Resolved: Expression of concern for Euro Surveill. 2020;25(32).Euro Surveill. 2020 Oct;25(39):201001en. doi: 10.2807/1560-7917.ES.2020.25.39.201001en. Euro Surveill. 2020. PMID: 33006304 Free PMC article. No abstract available.
Expression of concern in
-
Expression of concern for Euro Surveill. 2020;25(33).Euro Surveill. 2020 Aug;25(34):200827ec. doi: 10.2807/1560-7917.ES.2020.25.34.200827ec. Epub 2020 Aug 24. Euro Surveill. 2020. PMID: 32840204 Free PMC article. No abstract available.
Abstract
Background Rotavirus is a major cause of severe gastroenteritis in children worldwide. The disease burden has been substantially reduced in countries where rotavirus vaccines are used. Given the risk of vaccine-induced intussusception, the benefit–risk balance of rotavirus vaccination has been assessed in several countries, however mostly without considering indirect protection effects. Aim We performed a benefit–risk analysis of rotavirus vaccination accounting for indirect protection in France among the 2018 population of children under the age of 5 years. Methods To incorporate indirect protection effects in the benefit formula, we adopted a pseudo-vaccine approach involving mathematical approximation and used a simulation design to provide uncertainty intervals. We derived background incidence distributions from quasi-exhaustive health claim data. We examined different coverage levels and assumptions regarding the waning effects and intussusception case fatality rate. Results With the current vaccination coverage of < 10%, the indirect effectiveness was estimated at 6.4% (+/− 0.4). For each hospitalisation for intussusception, 277.0 (95% uncertainty interval: (165.0–462.1)) hospitalisations for rotavirus gastroenteritis were prevented. Should 90% of infants be vaccinated, indirect effectiveness would reach 57.9% (+/− 3.7) and the benefit–risk ratio would be 192.4 (95% uncertainty interval: 116.4–321.3). At a coverage level of 50%, indirect protection accounted for 27% of the prevented rotavirus gastroenteritis cases. The balance remained in favour of the vaccine even in a scenario with a high assumption for intussusception case fatality. Conclusions These findings contribute to a better assessment of the rotavirus vaccine benefit–risk balance.
Keywords: Rotavirus vaccine; benefit-risk ratio; indirect protection; intussusception; rotavirus gastroenteritis; simulation analysis.
Conflict of interest statement
Figures



Similar articles
-
A benefit-risk analysis of rotavirus vaccination, France, 2015.Euro Surveill. 2017 Dec;22(50):17-00041. doi: 10.2807/1560-7917.ES.2017.22.50.17-00041. Euro Surveill. 2017. PMID: 29258644 Free PMC article.
-
Benefit Versus Risk Assessment of Rotavirus Vaccination in France: A Simulation and Modeling Analysis.BioDrugs. 2018 Apr;32(2):139-152. doi: 10.1007/s40259-018-0273-6. BioDrugs. 2018. PMID: 29589230 Free PMC article.
-
Evaluating the potential risks and benefits of infant rotavirus vaccination in England.Vaccine. 2014 Jun 17;32(29):3604-10. doi: 10.1016/j.vaccine.2014.04.082. Epub 2014 May 9. Vaccine. 2014. PMID: 24814524
-
Rotavirus vaccines: a story of success.Clin Microbiol Infect. 2015 Aug;21(8):735-43. doi: 10.1016/j.cmi.2015.01.027. Epub 2015 Feb 11. Clin Microbiol Infect. 2015. PMID: 25680314 Review.
-
Impact of rotavirus vaccination on diarrheal disease burden of children in South America.Expert Rev Vaccines. 2024 Jan-Dec;23(1):606-618. doi: 10.1080/14760584.2024.2360212. Epub 2024 May 31. Expert Rev Vaccines. 2024. PMID: 38813689 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical